Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

This activity is supported by an educational grant from Amgen.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

CFS: Medical Crossfire®: An Oncologist’s Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment

CFS: Medical Crossfire®: An Oncologist’s Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment

Wednesday, November 7, 2018
1:40 PM - 3:10 PM

Registration: 1:10 PM - 1:40 PM

New York Marriott Marquis
Julliard Complex (5th Floor)
1535 Broadway
New York, NY 10036


Biosimilars are biologically derived medications that are highly similar to US Food and Drug Administration (FDA)–approved biologic products. Unlike small-molecule medications, biologic products are produced in living organisms, and small process changes may alter the final structure and function of the final protein product. As a result, slight differences in protein folding and glycosylation may be expected. However, through advanced testing and validation techniques, scientists and regulatory authorities can confirm a high degree of clinical similarity between biosimilar products and reference biologics. An understanding of the regulatory and manufacturing processes, and the extensive criteria for equivalence testing required for approval of a new biosimilar product, is crucial to confidence in using these medications among healthcare professionals and the patients they treat.

Several biosimilars are in late-stage regulatory development for use in breast cancer, including HER2-targeting agents, antiangiogenic medications, and febrile neutropenia prophylaxis treatments. In this Medical Crossfire® activity, by discussing regulatory requirements, manufacturing requirements, and clinical data supporting use of these medications, healthcare professionals who treat patients with breast cancer can prepare for optimal integration of these products into their clinical practice.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer with biosimilars are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Explain the developmental and regulatory processes by which biosimilars are manufactured and approved by the FDA
  2. Evaluate efficacy, safety, and equivalence from clinical trials of biosimilars for breast cancer treatment
  3. Address barriers related to the integration of biosimilars into the treatment of patients with breast cancer
  4. Increase awareness about emerging biosimilar agents currently in development for the treatment of breast cancer


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information



Become a Member

Forgot Password?
Calendar of Events
Filter By